P
127.12
-3.08 (-2.37%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Palvella Therapeutics, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.6
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 0.5 |
| 平均 | 0.63 |
|
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company’s lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company’s patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 22.87% |
| 机构持股比例 | 47.68% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 255.00 (HC Wainwright & Co., 100.60%) | 购买 |
| 中 | 232.50 (82.90%) | |
| 低 | 210.00 (Chardan Capital, 65.20%) | 购买 |
| 平均值 | 232.50 (82.90%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 124.51 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| BTIG | 25 Feb 2026 | 215.00 (69.13%) | 购买 | 128.60 |
| Mizuho | 25 Feb 2026 | 250.00 (96.66%) | 购买 | 128.60 |
| Chardan Capital | 24 Feb 2026 | 210.00 (65.20%) | 购买 | 120.41 |
| HC Wainwright & Co. | 24 Feb 2026 | 255.00 (100.60%) | 购买 | 120.41 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合